Get the Stockscreener App
1.35
9.40%
-0.14
After Hours:
1.35
Pyxis Oncology Inc stock is traded at $1.35, with a volume of 336.86K.
It is down -9.40% in the last 24 hours and down -12.34% over the past month.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
See More
Previous Close:
$1.49
Open:
$1.47
24h Volume:
336.86K
Relative Volume:
0.30
Market Cap:
$84.06M
Revenue:
-
Net Income/Loss:
$-73.79M
P/E Ratio:
-0.7337
EPS:
-1.84
Net Cash Flow:
$-77.44M
1W Performance:
-11.18%
1M Performance:
-12.34%
6M Performance:
-29.32%
1Y Performance:
+15.38%
1-Day Range:
$1.34
$1.47
1-Week Range:
$1.34
$1.5191
52-Week Range:
$0.8332
$5.55
Pyxis Oncology Inc Stock (PYXS) Company Profile
Name
Pyxis Oncology Inc
Sector
Industry
Phone
(617) 221-9059
Address
321 HARRISON AVENUE, BOSTON
Compare PYXS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.35 | 92.77M | 0 | -73.79M | -77.44M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Resumed | Stifel | Buy |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Nov-21-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-08-24 | Initiated | Stephens | Overweight |
| Aug-08-24 | Initiated | Stifel | Buy |
| May-07-24 | Resumed | Jefferies | Buy |
| Feb-09-24 | Initiated | BTIG Research | Buy |
| Jan-23-24 | Initiated | Leerink Partners | Outperform |
| Sep-05-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-02-21 | Initiated | BofA Securities | Neutral |
| Nov-02-21 | Initiated | Credit Suisse | Outperform |
| Nov-02-21 | Initiated | Jefferies | Buy |
View All
Pyxis Oncology Inc Stock (PYXS) Latest News
PYXS Technical Analysis & ETF Price Forecast - Intellectia AI
Will Pyxis Oncology Inc stock benefit from M A2025 Growth vs Value & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
PYXS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Can Pyxis Oncology Inc. expand its profit marginsWeekly Trade Review & Low Drawdown Investment Ideas - mfd.ru
PYXS Should I Buy - Intellectia AI
Can Pyxis Oncology Inc. stock hit record highs againWeekly Risk Report & AI Powered Buy/Sell Recommendations - mfd.ru
Street Watch: Can Pyxis Oncology Inc sustain its profitabilityJuly 2025 News Drivers & Fast Gain Stock Tips - baoquankhu1.vn
Can Pyxis Oncology Inc. sustain its profitabilityJuly 2025 Fed Impact & Capital Protection Trade Alerts - mfd.ru
What catalysts could drive Pyxis Oncology Inc. stock higherJuly 2025 Summary & Risk Managed Trade Strategies - mfd.ru
Pyxis Oncology Announces Interim CEO Amid Leadership Transition - The Globe and Mail
Pyxis Oncology (PYXS) taps board member Thomas Civik as interim CEO in leadership shift - Stock Titan
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Pyxis Oncology (PYXS) - The Globe and Mail
Pyxis Oncology appoints Thomas Civik as interim CEO By Investing.com - Investing.com Nigeria
Pyxis Oncology, Inc. Announces Chief Executive Officer Changes, Effective February 3, 2026 - marketscreener.com
Pyxis Oncology names Thomas Civik as interim CEO - marketscreener.com
Pyxis Oncology Appoints Thomas Civik as Interim CEO - citybiz
Pyxis Oncology appoints Thomas Civik as interim CEO - Investing.com
Pyxis Oncology Announces Interim CEO Appointment and - GlobeNewswire
Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Update - MarketBeat
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Pyxis Oncology (NASDAQ:PYXS) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Pyxis Oncology (NASDAQ:PYXS) Downgraded by Wall Street Zen to “Sell” - Defense World
Wall Street Zen Upgrades Pyxis Oncology (NASDAQ:PYXS) to “Hold” - Defense World
Wall Street Zen Upgrades Pyxis Oncology (NASDAQ:PYXS) to "Hold" - MarketBeat
Cancer drug developer Pyxis Oncology to join 2 November investor chats - Stock Titan
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff - The Spec
Pyxis Oncology Reports Increased Losses Amid Development Focus - MSN
Returns Recap: How Pyxis Oncology Inc. stock compares to growth peers2025 Fundamental Recap & Low Volatility Stock Recommendations - ulpravda.ru
Aug Action: Will Pyxis Oncology Inc. stock benefit from automationPortfolio Value Report & Precise Swing Trade Alerts - ulpravda.ru
Will Pyxis Oncology Inc. stock benefit from automationJuly 2025 Decliners & Consistent Income Trade Ideas - Улправда
Will Pyxis Oncology Inc. stock gain from government policiesJuly 2025 Final Week & Fast Entry Momentum Trade Alerts - Улправда
Is Pyxis Oncology Inc. stock a dividend growth opportunity2025 Key Lessons & Real-Time Chart Pattern Alerts - Улправда
The $537B Precision Pivot: Why Molecular Monitoring is the New Oncology Standard - The Globe and Mail
After-Hours Gainers: ALXO, GMED, ACRV, And Biotech Peers Rally On Trial Data And Earnings Updates - RTTNews
Pyxis Oncology, Inc.Common Stock (NQ: PYXS - FinancialContent
Is Pyxis Oncology Inc. stock recession proofHead and Shoulders Patterns & Create Your Free Watchlist Instantly - ulpravda.ru
PYXS Stock Price, Forecast & Analysis | PYXIS ONCOLOGY INC (NASDAQ:PYXS) - Chartmill
Pyxis Oncology (NASDAQ:PYXS) versus Kiora Pharmaceuticals (NASDAQ:KPRX) Head to Head Contrast - Defense World
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
PYXS,RPTX Dividends - Finviz
Goosehead Insurance Inc 2OX Stock Analysis and ForecastMomentum Trading Signals & Exceptional Return Capital - earlytimes.in
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Is Pyxis Oncology Inc. stock positioned well for digital economyShort-Term Trading Alerts & Easy Tools to Analyze Your Investment Risk - bollywoodhelpline.com
Pyxis Oncology Inc. (PYXS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Short Interest in Pyxis Oncology, Inc. (NASDAQ:PYXS) Drops By 57.3% - MarketBeat
Pyxis Oncology Stock Plunge: A Buy Signal? - StocksToTrade
Pyxis Oncology Stock Slides 73% With A 7-Day Losing Spree - Trefis
Would You Still Hold Pyxis Oncology Stock If It Fell Another 30%? - Trefis
Bear Alert: Is Pyxis Oncology Inc. stock a contrarian buy2025 Year in Review & Safe Entry Momentum Stock Tips - Улправда
Pyxis Oncology Inc Stock (PYXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.07%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):